tafamidis
Vyndaqel and Vyndamax (tafamidis) are transthyretin stabilizers from Pfizer. In the United States they treat transthyretin amyloid cardiomyopathy to reduce cardiovascular death and hospitalization, and in the European Union tafamidis delays nerve damage in early hereditary transthyretin amyloid polyneuropathy.
This page is based on FDA prescribing information and the EMA medicine record for tafamidis, cross-checked with DailyMed and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Transthyretin travels in the blood as a four-piece carrier. In amyloid disease the pieces come apart, misfold, and pile up as sticky deposits in the heart or nerves. Tafamidis acts like a clamp that holds the four pieces together, so they cannot break apart and form deposits, slowing the damage to the heart and peripheral nerves.
In simple terms
Tafamidis belongs to the transthyretin stabilizer class. Transthyretin is a protein that can become unstable, break apart, and form amyloid deposits in the heart, causing stiff, weakened heart muscle, or in peripheral nerves. Tafamidis binds transthyretin and stabilises it, preventing the formation of these protein deposits. In the heart this slows the progression of transthyretin amyloid cardiomyopathy and reduces cardiovascular death and hospitalizations; in early hereditary amyloid polyneuropathy it delays nerve impairment.
In depth
Tafamidis is a transthyretin stabilizer that selectively binds the thyroxine-binding sites of the transthyretin tetramer, stabilising it and slowing dissociation into monomers, the rate-limiting step in amyloid fibril formation. By reducing the pool of misfolding-competent monomers, it limits amyloid deposition in the myocardium and peripheral nerves. In wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy it reduces cardiovascular mortality and cardiovascular-related hospitalization, and in hereditary transthyretin amyloidosis with stage-1 symptomatic polyneuropathy it delays peripheral neurologic impairment.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How TTR stabilizers slow amyloid build-up
- Transthyretin normally circulates as a four-part complex that carries thyroid hormone and retinol.
- In amyloid disease the pieces come apart, misfold, and pile up as sticky deposits in the heart or nerves.
- The drug binds the thyroxine pockets on the tetramer and holds it together.
- With the tetramer held together, less amyloid forms, so damage to the heart and peripheral nerves slows.
Target: Transthyretin (TTR)
A carrier protein that normally circulates as a stable four-part unit; when it destabilises, fragments misfold and build up as amyloid deposits in the heart or nerves.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization
Approved uses in European Union
EMA- For the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy, to delay peripheral neurologic impairment
Official sources
The statements on this page trace back to these records.
- Vyndaqel (tafamidis) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: VYNDAQEL and VYNDAMAX (tafamidis) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: tafamidis prescribing information
U.S. Food and Drug Administration
- MedlinePlus: tafamidis
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.